The New England journal of medicine, 2023-11, Vol.389 (20), p.1851-1861
- Hadoux, Julien
- Elisei, Rossella
- Brose, Marcia S.
- Hoff, Ana O.
- Robinson, Bruce G.
- Gao, Ming
- Jarzab, Barbara
- Isaev, Pavel
- Kopeckova, Katerina
- Wadsley, Jonathan
- Führer, Dagmar
- Keam, Bhumsuk
- Bardet, Stéphane
- Sherman, Eric J.
- Tahara, Makoto
- Hu, Mimi I.
- Singh, Ravinder
- Lin, Yan
- Soldatenkova, Victoria
- Wright, Jennifer
- Lin, Boris
- Maeda, Patricia
- Capdevila, Jaume
- Wirth, Lori J.
2023
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Hadoux, Julien
- Elisei, Rossella
- Brose, Marcia S.
- Hoff, Ana O.
- Robinson, Bruce G.
- Gao, Ming
- Jarzab, Barbara
- Isaev, Pavel
- Kopeckova, Katerina
- Wadsley, Jonathan
- Führer, Dagmar
- Keam, Bhumsuk
- Bardet, Stéphane
- Sherman, Eric J.
- Tahara, Makoto
- Hu, Mimi I.
- Singh, Ravinder
- Lin, Yan
- Soldatenkova, Victoria
- Wright, Jennifer
- Lin, Boris
- Maeda, Patricia
- Capdevila, Jaume
- Wirth, Lori J.
- Titel
- Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer
- Ist Teil von
- The New England journal of medicine, 2023-11, Vol.389 (20), p.1851-1861
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2023
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Selpercatinib, an oral, selective, brain-penetrant RET kinase inhibitor, was compared with multikinase inhibitors in advanced medullary thyroid cancer. At 12 months, progression-free survival was 86.8% and 65.7%, respectively.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2309719Titel-ID: cdi_proquest_miscellaneous_2881247492
- Format
- –
- Schlagworte
- Adverse events, Antineoplastic Agents - adverse effects, Antineoplastic Agents - therapeutic use, Cancer, Confidence intervals, Disease Progression, Endocrinology, Genetics, Hematology, Humans, Inhibitor drugs, Laboratories, Metastasis, Mutants, Mutation, Oncology, Oncology General, Piperidines - adverse effects, Piperidines - therapeutic use, Proto-Oncogene Proteins c-ret - genetics, Pyridines - adverse effects, Pyridines - therapeutic use, Quinazolines - adverse effects, Quinazolines - therapeutic use, Statistical analysis, Survival, Targeted cancer therapy, Thyroid cancer, Thyroid Disease, Thyroid Neoplasms - drug therapy, Thyroid Neoplasms - genetics, Treatments in Oncology, Tyrosine kinase inhibitors